

Clinical Updates from San Antonio
Clinical Update #2: HER2- Advanced Breast Cancer – Heavily Pretreated Patients

References

Tweet 2

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Rugo HS, Bardia A, Marme F, et al. Sacituzumab govitecan in hormone teceptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol*. 2022;40(29):3365-3376. doi:10.1200/JCO.22.01002

Rugo HS, Bardia A, Marmé F, et al. LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). *Ann Oncol*. 2022;33:S1386.
doi:10.1016/j.annonc.2022.08.012

Rugo H, Bardia A, Marmé F, et al. GS5-11 Sacituzumab govitecan (SG) vs treatment of physician's choice (TPC): efficacy by trop-2 expression in the TROPiCS-02 study of patients (Pts) with HR+/HER2– metastatic breast cancer (mBC). Presented at: SABCS; December 9, 2022; San Antonio, TX. Accessed December 1, 2022.

TRODELVY® (sacituzumab govitecan-hziy) [prescribing information]. Immunomedics, Inc. Approved 2020. Revised June 2022.
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process>

Glossary

aBC, advanced breast cancer
ADC, antibody-drug conjugate
AE, adverse event
CBR, clinical benefit rate
CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor
Chemo, chemotherapy
CI, confidence interval
ET, endocrine therapy
HER2, human epidermal growth factor receptor 2
HR, hazard ratio
HR+, hormone receptor positive
mBC, meastatic breast cancer
mDOR, median duration of response
mOS, median overall survival
mPFS, median progression-free survival
ORR, objective response rate
OS, overall survival

Ph3, phase 3

PFS, progression-free survival

SG, sacituzumab govitecan

TOP1, topoisomerase 1

Trop-2, trophoblast cell-surface antigen-2

w/, with